4th European Conference on Schizophrenia Research
Together for better treatment and care

Joint thematic congress of the European Scientific Association on Schizophrenia and other Psychoses (ESAS), the Competence Network on Schizophrenia (CNS), the European Psychiatric Association (EPA), and German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

26 – 28 September 2013
Berlin, Germany

in cooperation with

World Psychiatric Association (WPA) and its Section on Schizophrenia

Final Programme

accredited by the European Council for Continuing Education (EACCME) with 16 CME credits
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Address</td>
<td>3</td>
</tr>
<tr>
<td>Conference Organisation</td>
<td>5</td>
</tr>
<tr>
<td>Conference Information</td>
<td>6</td>
</tr>
<tr>
<td>Format Descriptions/CME Credits</td>
<td>8</td>
</tr>
<tr>
<td>Opening Ceremony and Welcome Reception</td>
<td>10</td>
</tr>
<tr>
<td>Overview Scientific Programme</td>
<td>11</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td></td>
</tr>
<tr>
<td>Thursday, 26 September</td>
<td>14</td>
</tr>
<tr>
<td>Friday, 27 September</td>
<td>24</td>
</tr>
<tr>
<td>Saturday, 28 September</td>
<td>39</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>49</td>
</tr>
<tr>
<td>Floorplan</td>
<td>49</td>
</tr>
<tr>
<td>Index Chairpersons, Authors and Presenters</td>
<td>51</td>
</tr>
</tbody>
</table>
Dear Colleagues,

In recent years a growing body of cutting-edge schizophrenia research was performed and new evidence was generated with regard to aetiology, symptomatology, treatment and care of schizophrenia. Treatment research on new pharmacological targets and novel mechanisms of action demonstrated encouraging efficacy across a range of symptoms allowing for a better and personalised treatment. New imaging techniques were developed to gain new insights in the pathophysiology of this disorder. Some recent findings may help to diagnose schizophrenia earlier in the course and to predict treatment response. Yet we are still far away from understanding the underlying causes and complexity of schizophrenia corresponding to heterogeneous patient needs. Publication of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) earlier this year has led to an intense and controversial discussion beyond the psychiatric community becoming a matter of public interest and media coverage.

The scientific programme of the European Conference on Schizophrenia Research (ECSR) critically discusses recent scientific advances, deals with current controversies, and updates the scientific knowledge about schizophrenia and translate it into clinical practice. The need to have a forum for scientific exchange and to address clinical challenges encouraged, in 2007, the Competence Network on Schizophrenia to initiate this biennial European schizophrenia congress which will be held for the fourth time.

According to this year’s motto “Together for better treatment and care”, the scientific programme of the ECSR provides a comprehensive overview on recent research projects and developments in schizophrenia treatment and documents the broad range of topics to be presented in plenary lectures, (prearranged and submitted) symposia, workshops, oral presentations and poster sessions. Treatment of negative symptoms, deficits in social cognition, non-adherence, and the promotion and implementation of evidence-based strategies to ensure standards of care as well as basic research topics will be addressed by high quality contributions from acknowledged experts, young scientists, and clinicians.
As in previous years, the co-organising psychiatric associations and their respective schizophrenia sections play an important role in this joint thematic conference. On occasion of the third ECSR the European Scientific Association on Schizophrenia and other Psychoses (ESAS) took over the responsibility to organise future ECSRs. Yet, the tasks of ESAS are certainly not limited to organising this conference; further tasks may be the identification of emerging issues for schizophrenia research and, as a consequence, outlining a research agenda and initiation of collaborations and networking activities.

On behalf of the Scientific Committee and the organisers, I cordially welcome you at the 4th European Schizophrenia Research Conference and thank you for your attendance. I wish all of us inspiring days.

Sincerely yours,

Wolfgang Gaebel
Congress President
President European Scientific Association on Schizophrenia and other Psychoses
Speaker of the Competence Network on Schizophrenia
ORGANISERS

European Scientific Association on Schizophrenia and other Psychoses (ESAS)

Competence Network on Schizophrenia (CNS)

European Psychiatric Association (EPA) and its Section on Schizophrenia

German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

PROFESSIONAL CONFERENCE ORGANISER
Hanser & Co GmbH
Postfach 12 21
22882 Barsbüttel, Germany
Phone: +49 – 40 – 670 88 20
Fax: +49 – 40 – 670 32 83
Email: schizophrenia@cpo-hanser.de

SCIENTIFIC PROGRAMME COMMITTEE
Wolfgang Gaebel, Germany
Congress President

George Awad, Canada
Finn Bengtsson, Sweden
Dinesh Bhugra, UK
Gerd Buchkremer, Germany
George Christodoulou, Greece
Peter Falkai, Germany
Silvana Galderisi, Italy
Wagner F. Gattaz, Brazil
Birte Glenthoj, Denmark
Philipp Gorwood, France
Heinz Häfner, Germany
Cyril Höschl, Czech Republic
Joachim Klosterkötter, Germany
Valery Krasnov, Russia
Shôn Lewis, UK
Jan Libiger, Czech Republic
Wolfgang Maier, Germany
Mario Maj, Italy
Stephen Marder, USA
Patrick McGorry, Australia
Hans-Jürgen Möller, Germany
Merete Nordentoft, Denmark
Michael Owen, UK
Victor Peralta, Spain
Wulf Rössler, Switzerland
Pedro Ruiz, USA
Bernard Sabbe, Belgium
Norman Sartorius, Switzerland
Frank Schneider, Germany
Wolfgang Wölwer, Germany
Til Wykes, UK

LOCAL ORGANISER
PsychoseNetz e.V.
Wolfgang Gaebel, Wolfgang Wölwer,
Viktoria Toeller
c/o Department of Psychiatry
and Psychotherapy
Heinrich-Heine-University Düsseldorf
LVR Clinic Center
Bergische Landstraße 2
40629 Düsseldorf, Germany

SCIENTIFIC SECRETARIAT
European Scientific Association on Schizophrenia and other Psychoses (ESAS) e.V.
Wolfgang Gaebel, Wolfgang Wölwer,
Viktoria Toeller
c/o Department of Psychiatry and Psychotherapy
Heinrich-Heine-University Düsseldorf, Germany
CONFERENCE VENUE
Urania Berlin e.V.
An der Urania 17
10787 Berlin, Germany
www.urania.de

CONFERENCE REGISTRATION COUNTER
All conference material and documentation are available at the conference registration counter located in the foyer on the ground floor of the Urania.

OPENING HOURS
<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 26 Sept. 2013</td>
<td>08.00 – 18.00 h</td>
</tr>
<tr>
<td>Friday, 27 Sept. 2013</td>
<td>08.00 – 19.45 h</td>
</tr>
<tr>
<td>Saturday, 28 Sept. 2013</td>
<td>08.00 – 16.00 h</td>
</tr>
</tbody>
</table>

During these opening hours the conference counter can be reached at:
Phone: +49 – 30 – 2100 81 63

REGISTRATION FEE

ON-SITE REGISTRATION

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members of ESAS, CNS, EPA, DGPPN, WPA</td>
<td>EUR 490,00</td>
</tr>
<tr>
<td>Non-members</td>
<td>EUR 540,00</td>
</tr>
<tr>
<td>Trainees *</td>
<td>EUR 440,00</td>
</tr>
</tbody>
</table>

* Non-tenured junior scientists or clinical residents in training under 35 years [Trainee status must be confirmed by a certificate in writing by head of department and copy of passport].

ON-SITE REGISTRATION

On-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the number of on-site registered delegates, availability of conference documentation may be limited.

NAME BADGES

Participants are kindly requested to wear their name badge at all times during the conference including the Opening Ceremony and Welcome Reception.

CONFERENCE LANGUAGE

The conference language is English. Simultaneous translation will not be provided.

PROGRAMME CHANGES

The organisers cannot assume liability for any changes in the conference programme due to external or unforeseen circumstances.

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be handed out upon demand at the registration counter.

ABSTRACT BOOK

All accepted abstracts are published in an abstract book as a supplement of the European Archives of Psychiatry and Clinical Neurosciences (EAPCN). The abstract book will be handed out together with the conference documentation at the registration counter.

MEDIA CHECK

The Media Check is located in hall Keppler on the first floor of the Urania. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their session but at the latest 90 minutes prior to the presentation. The presentation will be transferred to a special conference notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook.

OPENING HOURS

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 26 Sept. 2013</td>
<td>08.00 – 18.00 h</td>
</tr>
<tr>
<td>Friday, 27 Sept. 2013</td>
<td>08.00 – 19.00 h</td>
</tr>
<tr>
<td>Saturday, 28 Sept. 2013</td>
<td>08.00 – 15.00 h</td>
</tr>
</tbody>
</table>
**POSTER EXHIBITION**
The poster exhibition is located in the foyers on the ground floor of the Urania. Posters will be on display for the entire time of the conference. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates, daily guided poster tours will take place chaired by senior scientists:

**Thursday, 26 Sept. 2013**
Guided Poster Tours P-01 – P-04: 13.30 – 14.30 h

**Friday, 27 Sept. 2013**
Guided Poster Tours P-05 – P-09: 13.30 – 14.30 h

**Saturday, 28 Sept. 2013**
Guided Poster Tours P-10 – P-13: 13.30 – 14.30 h

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

**Set-up and dismantling times for posters**

**Set-up:**
Thursday, 26 Sept. 2013:  08.00 – 10.00 h

**Dismantling:**
Saturday, 28 Sept. 2013:  16.00 – 17.00 h

Posters which have not been removed within the indicated dismantling time will be disposed.

**COFFEE BREAKS**
Coffee, tea and mineral water will be served free of charge to all registered delegates during the morning and afternoon coffee breaks from Thursday, 26 September to Saturday, 28 September 2013. Coffee bar stations are located on the first floor and in the foyer of the ground floor next to the poster exhibition.

**LUNCH AND RESTAURANTS**
A lunch snack will be served to all registered delegates during the lunch breaks from Thursday, 26 September to Saturday, 28 September 2013 in the foyer of the ground floor next to the poster exhibition and on the first level. The conference venue further provides a restaurant on the first floor where snacks and food are available on cash basis.

**MOBILE PHONES**
Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

**INSURANCE**
The conference fee does not include insurance. All participants are advised to arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of residence.

**HOW TO GET TO THE URANIA:**

**By plane**
The congress venue Urania is just 8 km from Tegel airport and 22 km from Schönefeld airport.

**By train**
Centrally located within the heart of Berlin close to Tiergarten and Lützowplatz, the Urania is just 5 km from Berlin’s main train station, and only a few minutes by car or taxi.

**By car**
Access to Berlin via the motorways A111, A113 or A115 with direction to Tiergarten / Lüttzowplatz. The Urania is located in the street "At the Urania", crossed by the Kurfürstenstrasse.

**By public transportation**
The Urania is well connected within the public transport network via U-Bahn lines 1, 2, 3 and 4 at the Wittenbergplatz and Nollendorfplatz U-Bahn stations, as well as via bus lines.

**PARKING**
The Urania provides 40 parking places free of charge in the courtyard.
The scientific programme will comprise the following formats:

PLENARY LECTURES
Invited lectures of 45 min each, covering current hot spots in schizophrenia research and given by leading European experts.

SYMPOSIA
Pre-arranged or submitted symposia of 90 min each, including four presentations and 15 min time for discussion covering major topics of the conference. Both symposia with a clear scientific focus and those with a clear clinical focus will be included.

WORKSHOPS
Pre-arranged workshops allowing for detailed discussion on scientific topics in particular serving transnational collaboration within Europe. Participation is included in the registration fee. For W-01 and W-02 preliminary registration is required.

ORAL PRESENTATION SESSIONS
Submitted presentations grouped by topics into thematic oral sessions of 90 min, including six or seven papers each.

POSTER SESSIONS
Submitted presentations grouped by topics into thematic guided poster sessions.

CME ACCREDITATION
The 'European Scientific Association on Schizophrenia and other Psychoses (ESAS)' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS).

www.uems.net.

The '4th European Conference on Schizophrenia Research (ECSR)' is designated for a maximum of 16 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for EMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Submit Your Abstract
Abstract Submission Deadline: 1 October 2013

22nd EUROPEAN CONGRESS OF PSYCHIATRY

Munich, Germany 1-4 March 2014

EUROPEAN PSYCHIATRY FOCUSING ON BODY AND MIND

www.epa-congress.org
OPENING AND WELCOME RECEPTION

THURSDAY, 26 SEPTEMBER 2013

Opening Ceremony

09.15 – 10.15 h Humboldt Hall

▶ Presidential Address

Professor Wolfgang Gaebel, Düsseldorf Germany
Congress President, Chair of the European Scientific Association on Schizophrenia and other Psychoses (ESAS), Speaker of the Competence Network on Schizophrenia (CNS)

▶ Welcome Addresses

Professor Danuta Wasserman, Stockholm, Sweden
President of the European Psychiatric Association (EPA)

Professor Wolfgang Maier, Bonn, Germany
President of the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

Professor Tarek Okasha, Cairo, Egypt
Secretary for Scientific Meetings of the World Psychiatric Association (WPA)

Professor Andi Jayalangkara Tanra, Makassar, Indonesia
President of the Asian College for Schizophrenia Research (ACSR)

▶ Areteaus-Award Ceremony – Laureate 2013

Welcome Reception

19.00 – 20.00 h Foyers

At the end of the scientific sessions participants are invited to join the Welcome Reception in the foyers of the first level of the Urania. Finger food and drinks will be provided.
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Humboldt</th>
<th>Kleist</th>
<th>Loft A</th>
<th>Einstein</th>
<th>Loft C</th>
<th>Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15</td>
<td>Opening</td>
<td>Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15</td>
<td>PL-01</td>
<td>Toward new</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>approaches</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>to classify</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>psychotic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>spectrum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>disorders:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>the NIMH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Domain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>S-01</td>
<td>Beyond DSM-5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and ICD-11:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>how should</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>psychotic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>disorders be</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>conceptualized</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and diagnosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>in the future</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>S-02</td>
<td>Preventive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>out-patient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>approaches</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>to schizophrenia-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>associated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>violence and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>delinquency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>S-03</td>
<td>Apathy in</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>– clinical,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>experimental</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>therapeutic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>approaches</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>S-04</td>
<td>The mild</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>encephalo-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>tic hypothesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>of schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>updated: low level neuroinflammation, autoimmunity, volume transmission, treatment approaches</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.30 – 14.30 h</td>
<td>Guided Poster Tours P-01 to P-04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P-01: Treatment (drug) 1</td>
<td>P-02: Neuropsychology 1</td>
<td>P-03: Comorbidity and psychopathology</td>
<td>P-04: Course and outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>S-05</td>
<td>Approaches</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>for predicting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>development of psychiatry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>S-06</td>
<td>The risks and benefits of antipsychotic polypharmacy: clinical relevance and development of evidence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>S-07</td>
<td>Dimensional concepts of psychosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>O-01</td>
<td>Neurobiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>W-01: Part 1 How to write manuscripts for publication in English language scientific journals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>S-08</td>
<td>Biological pathways to psychosis: the role of stress</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>S-09</td>
<td>Suicide prevention in schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>S-10</td>
<td>Eye movement research: a window to cognitive impairments in schizophrenia?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>S-11</td>
<td>Microglia in schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>W-01: Part 2 How to write manuscripts for publication in English language scientific journals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.15</td>
<td>PL-02</td>
<td>Shifting paradigms for therapeutic discovery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00</td>
<td>Welcome Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Registration Counter**
Opening Hours: 08.00 – 18.00
<table>
<thead>
<tr>
<th>Time</th>
<th>Humboldt</th>
<th>Kleist</th>
<th>Loft A</th>
<th>Einstein</th>
<th>Loft C</th>
<th>Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-10.00</td>
<td>S-12 Negative symptoms - impact and therapeutic options</td>
<td>S-13 Progression in brain tissue loss, antipsychotic medication, cognition and outcomes in schizophrenia - the Northern Finland 1966 Birth Cohort Study</td>
<td>S-14 Translational genetics for psychiatric illnesses</td>
<td>O-02 Neuropsychology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-12.00</td>
<td>S-15 The future of psychopathology in the light of current neuroscience</td>
<td>S-16 New approaches to cognitive behavior therapy for psychosis</td>
<td>S-17 Epigenetic dysregulation in schizophrenia</td>
<td>O-03 Functional Neuroimaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15-13.00</td>
<td>PL-03 Structure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric research</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00-14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lunch Break</td>
<td></td>
</tr>
</tbody>
</table>
| 13.30-14.30 |  |  |  |  | **Guided Poster Tours P-05 to P-09**
<p>| 14.30-15.30 | S-18 Perspectives in schizophrenia research: emerging research issues | S-19 Should continuous antipsychotic medication be recommended after first episode psychosis? | S-20 The role of neuroinflammation in schizophrenia | S-21 Experimental psychopathology of psychosis | W-02: Part 1 How to apply for EU-funding |
| 16.00-18.00 | S-22 From structure to functioning: neurobiological candidates for the prediction of psychoses | S-23 Implementation of early intervention services for young people with first episode psychosis: rationale, evidence and practical experiences from Europe | S-24 Studies using structural and functional neuroimaging to advance understanding of schizophrenia | O-04 Comorbidity | W-02: Part 2 How to apply for EU-funding |
| 18.15-19.45 | S-25 Nosology in the schizophrenic psychoses: new insight from functional neuroimaging and genetics | S-26 The consequences of childhood trauma in psychotic disorders | S-27 Progress in neuropathological post-mortem findings in schizophrenia | O-05 Course and outcome |  |</p>
<table>
<thead>
<tr>
<th>Room</th>
<th>Humboldt</th>
<th>Kleist</th>
<th>Loft A</th>
<th>Einstein</th>
<th>Loft C</th>
<th>Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30 –</td>
<td>S–28</td>
<td>The high risk state for psychosis</td>
<td>S–29</td>
<td>S–30</td>
<td>O–06</td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td></td>
<td></td>
<td>The role of oligodendrocytes in schizophrenia: disease-inherent versus treatment-induced abnormalities</td>
<td>Oscillations and synchrony in cortical networks in schizophrenia</td>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>Coffee</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td></td>
<td>International perspectives of quality of care and integration of persons with schizophrenia</td>
<td>Single symptom approaches in schizophrenia: neuronal correlates of auditory hallucinations and language related symptoms</td>
<td>The schizophrenia motor dimension: clinical relevance and neurobiology</td>
<td></td>
</tr>
<tr>
<td>PL–04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15 –</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>Massage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunch Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 –</td>
<td>S–34</td>
<td>Obsessive–compulsive symptoms in schizophrenia</td>
<td>S–35</td>
<td>S–36</td>
<td>O–07</td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td></td>
<td></td>
<td>Psychological treatments for people with schizophrenia</td>
<td>Animal models of schizophrenia facing the complexity of genotype, environmental factors and phenotype</td>
<td>Structural neuroimaging</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Programme – Thursday, 26 September 2013

#### PL-01 Plenary Lectures

**10.15 – 11.00 h Humboldt Hall**

**Toward new approaches to classifying psychotic spectrum disorders: the NIMH Research Domain Criteria Project**

*Chair: S. Galderisi, Naples, Italy*

**PL-01-001**

Toward new approaches to classifying psychotic spectrum disorders: the NIMH Research Domain Criteria Project

*B. N. Cuthbert, Bethesda, USA*

#### S-01 Symposia

**11.30 – 13.00 h Humboldt Hall**

**Beyond DSM-5 and ICD-11: how should psychotic disorders be conceptualized and diagnosed in the future?**

*Chairs: A. Heinz, Berlin, Germany*  
*W. Gaebel, Düsseldorf, Germany*

**S-01-001**

Functional impairment – a mandatory criterion for mental disorders?  
*W. Gaebel, Düsseldorf, Germany*

**S-01-002**

How to distinguish between symptoms of a mental disease and impairments of (social) functions  
*A. Heinz, Berlin, Germany*  
*E. Friedel*

**S-01-003**

Are there specific symptoms that guide schizophrenia diagnosis?  
*S. Galderisi, Naples, Italy*

**S-01-004**

Can key symptoms of schizophrenia be matched to brain systems?  
*W. Strik, Bern, Switzerland*  
*T. Dierks*

#### S-02 Symposia

**11.30 – 13.00 h Kleist Hall**

**Preventive outpatient treatment approaches for schizophrenia-associated violence and delinquency**

*Chairs: C. Luckhaus, Düsseldorf, Germany*  
*S. Hodgins, Montreal, Canada*

**S-02-001**

The multifactorial basis of violence in schizophrenia  
*S. Hodgins, Montreal, Canada*

**S-02-002**

A psychoeducational intervention programme to reduce compulsory hospital readmission in the Canton of Zurich  
*B. Lay, Zurich, Switzerland*  
*T. Schönenerberger, M. Bleiker, S. Lengler, C. Blank, W. Rössler*

**S-02-003**

A preventive outpatient clinic for high-risk-of-violence patients in the region of Ansbach, Bavaria  
*J. Nitschke, Ansbach, Germany*  
*C. Luckhaus*

**S-02-004**

A complex-therapeutic intervention programme for schizophrenia outpatients targeted at reducing violent offending and compulsory detention in Düsseldorf, North Rhine-Westphalia  
*C. Luckhaus, Düsseldorf, Germany*
**S-03 SYMPOSIA**

11.30 – 13.00 h  
Loft A

Apathy in schizophrenia – clinical, experimental and therapeutic approaches  
*Chairs: S. Kaiser, Zurich, Switzerland  
A. Aleman, Groningen, The Netherlands*

**S-03-001**  
Apathy in first episode psychosis: similarities and differences to other brain disorders  
*A. Faerden, Oslo, Norway*

**S-03-002**  
Apathy as a disturbance of motivational and cognitive processes subserving goal-directed behavior  
*S. Kaiser, Zurich, Switzerland*

**S-03-003**  
Role of frontostriatal and frontoparietal networks in apathy  
*A. Aleman, Groningen, The Netherlands*

**S-03-004**  
Bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: findings from a double-blind randomized controlled trial  
*J. Diabac-De Lange, Groningen, The Netherlands  
L. Bais, A. Aleman, H. Knegtering*

**S-04 SYMPOSIA**

11.30 – 13.00 h  
Einstein Hall

The mild encephalitis hypothesis of schizophrenia updated: low level neuro-inflammation, autoimmunity, volume transmission, treatment approaches  
*Chairs: K. Bechter, Guenzburg, Germany  
B. Lennox, Oxford, United Kingdom*

**S-04-001**  
Antiinflammation and psychoimmunomodulation in schizophrenia  
*E. Weidinger, Munich, Germany  
N. Müller*

**S-04-002**  
Autoimmunity to NMDA receptors in schizophrenia  
*B. Lennox, Oxford, United Kingdom*

**S-04-003**  
Volume transmission balancing wiring (e.g. synaptic) transmission  
*D. Borroto-Escuela, Stockholm, Sweden  
K. Fuxe*

**S-04-004**  
The mild encephalitis hypothesis of schizophrenia updated  
*K. Bechter, Guenzburg, Germany*
P-01–006
Adverse metabolic effects associated with use of long-acting antipsychotic injections in the maintenance treatment of chronic schizophrenia
M. Gloria, Barcelona, Spain
G. Español, V. Valles, M. Montoro, A. M. Fargas

P-01–008
Descriptive analysis of schizophrenic patients in regular control in an atypical antipsychotic program in Chile
A. Armijo, Santiago, Chile
J. Villarroel, F. Valenzuela, D. Castillo, H. Silva

P-01–009
Prediction of antipsychotic therapy results basing on GSTM1 gene polymorphism in schizophrenic patients with different admission rate
V. Obyedkov, Minsk, Belarus
O. Skugarevsky, I. Halayenka

P-01–010
DTNBP1, HSPs and TAAR6 variations influence schizophrenic phenotype and treatment response
T.-Y. Jun, Seoul, Republic of Korea
C.-U. Pae

P-01–011
Neuroleptic malignant syndrome and swan neck deformity
E. Neroutsos, Elefsina-Athens, Greece
A. Graikiotis, J. Ntampos, M. Fiste, N. Lytra, E. Thermou
P-02  POSTER SESSIONS

13.30 – 14.30 h  Foyer

Neuropsychology 1
Chair:  M. Green, Sydney, Australia

P-02-001
Anticipation and recall of emotions in subclinical negative symptoms – an experimental study in a social context
M. Engel, Hamburg, Germany
T. M. Lincoln, A. Fritzsche

P-02-003
Different strategies of schizophrenia patients in the visual exploration of social stimuli
K. Drusch, Düsseldorf, Germany

P-02-004
Neurophysiological correlates of defective emotional processing in schizophrenic patients with chronic auditory hallucinations
E. Grasa, Barcelona, Spain

P-02-005
Neural underpinnings of inhibitory control in schizophrenia patients with a history of violence: a high-density electrical mapping study
G. Andrade, Bronx, New York, USA
J. Butler, M. Krakowski, J. Foxe, P. De Sanctis

P-02-006
Early sensory-perceptual contributions to emotional processing deficits in schizophrenia patients with a history of violent behavior
W. Ritter, New York, USA
P. De Sanctis, G. N. Andrade, J. S. Butler, M. I. Krakowski, J. J. Foxe

P-02-007
Affectively valenced stimuli modulate different processing stages of the inhibitory control circuit in schizophrenia patients with and without a history of violence
P. De Sanctis, New York, USA
J. J. Foxe, G. N. Andrade, P. Czobor, M. I. Krakowski

P-02-008
Metacognitive beliefs and thought control strategies in early psychosis
T. Østefjells, Oslo, Norway
R. Hagen, J. I. Røssberg

P-02-010
The integration of evidence is associated with neurocognitive capabilities in schizophrenia
S. Eifler, Mannheim, Germany

P-02-011
Interpersonal decentering in patients with schizophrenia
K. Hosakova, Bilovec, Czech Republic
M. Lecbych
<table>
<thead>
<tr>
<th>P-03-001</th>
<th>Immigrants do not show a specific psychosis symptom profile using a cross-culturally validated model of the PANSS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-03-002</th>
<th>Family factor of adaptation of patients with schizophrenic disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Gutkevich, Tomsk, Russia</td>
<td>O. Danilenko, M. Zinchuk, A. Semke</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-03-003</th>
<th>Family assessment among patients with various mental disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. Sadek, Cairo, Egypt</td>
<td>S. Rabei</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-03-004</th>
<th>Clinical-dynamic characteristics of schizophrenia associated with somatic pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>V. Lebedeva, Tomsk, Russia</td>
<td>A. Semke, E. Yurovskaya</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-03-005</th>
<th>Alexithymia is associated with psychotic and hypomanic symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Joukamaa, Tampere, Finland</td>
<td>S. Luutonen, R. K. Salokangas</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-03-006</th>
<th>Megalomania in dementia paralytica</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Daey Ouwens, Venray, The Netherlands</td>
<td>E. Lens, A. Ott, P. Koehler, W. Verhoeven</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-03-007</th>
<th>Schizophrenia-like psychosis and concurrent Substance Abuse: descriptive analysis and phenomenological approach in a Colombian inpatient early phase rehabilitation program</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Zuleta, Bogotá, Colombia</td>
<td>C. Rodriguez, G. Oviedo, F. Muñoz, J. Navarro</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-03-008</th>
<th>Alcohol use in schizophrenic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Del Carmen Garcia Mahia, A Coruña, Spain</td>
<td>E. Roman Fernandez, M. Vidal Millares</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-03-010</th>
<th>Prevalence of risk factors in homicidal behavior in schizophrenic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Aliko, Tirane, Albania</td>
<td>A. Kazaferi</td>
</tr>
</tbody>
</table>
Thursday, 26 September 2013 – SCIENTIFIC PROGRAMME

P-04 POSTER SESSIONS
13.30 – 14.30 h Foyer
Course and outcome
Chair: to be announced

P-04-001
Duration of untreated psychosis in patients with a first episode psychosis in a high-income versus a low- and middle income-region
N. Mossaheb, Vienna, Austria

P-04-002
Characteristics of illnesses and their course within the „psychotic continuum“ – predictive value for current psychopathology, cognition and functional outcome
J. Hallaschek, Halle, Germany
S. Watzke

P-04-003
Metacognition and negative symptoms in first episode psychosis: cross-sectional and longitudinal findings
A. Macbeth, Elgin, United Kingdom
H. McLeod, A. Gumley, M. Schwannauer, P. Lysaker, G. Dimaggio

P-04-004
Comparative of adolescent and adult onset psychosis: one year follow up
M. Dolz, Esplugues de Llobregat (BCN), Spain
J. Tor, J. Carlson, B. Sánchez, M. Pardo, D. Muñoz, A. Barajas, I. Baños, J. Usall, S. Ochoa

P-04-006
Factors affecting health related quality of life in psychiatric inpatients during treatment
G. Lyrakos, Nikaia, Greece
V. Spinoris, I. Spyropoylos

P-04-008
High religiousness, less perspective-taking and social suffering distinguish stable schizophrenia patients
R. Duñó, Sabadell, Spain
S. Díaz-Morán, A. Tobeña

P-04-010
Schizophrenia with obsessive–compulsive disorder comorbidity – clinical and treatment particularities
A. Ciobanu, Bucharest, Romania
### S-05 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Humboldt Hall</td>
<td>Approaches for predicting development of psychosis</td>
</tr>
</tbody>
</table>

Organised by the Competence Network on Schizophrenia (CNS)

**Chairs:** M. Marshall, Manchester, United Kingdom  
J. Klosterkötter, Cologne, Germany

- **S-05-001**  
  Prognostic and therapeutic validity of the Atenuated Psychosis Syndrome  
P. Fusar-Poli, London, United Kingdom

- **S-05-002**  
  The epidemiologic perspective of risk identification and psychosis prediction  
I. Kelleher, Dublín, Ireland  
A. Murtagh, C. Molloy, S. Roddy, M.C. Clark, M. Harley, M. Cannon

- **S-05-003**  
  Predicting psychosis in clinical practice—outcome of patients seen in a NHS Prodrome Clinic  
M. Marshall, Manchester, United Kingdom  
C. Johnson, K. Neelam, R. Drake

- **S-05-004**  
  How to improve the prediction of psychosis  
S. Ruhrmann, Cologne, Germany

### S-06 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Kleist Hall</td>
<td>The risks and benefits of antipsychotic polypharmacy: clinical relevance and development of evidence</td>
</tr>
</tbody>
</table>

**Chairs:** J. Cordes, Düsseldorf, Germany  
W. Fleischhacker, Innsbruck, Austria

- **S-06-001**  
  Antipsychotic drug target occupancy in PET studies: lessons for combining antipsychotics?  
G. Gründer, Aachen, Germany

- **S-06-002**  
  When to switch or combine: time course for response in antipsychotic drug treatment  
M. Jäger, Guenzburg, Germany

- **S-06-003**  
  The development of multiple antipsychotic combination treatment in comparison between European countries – findings from the AMSP project  
A. Konstantinidis, Vienna, Austria  
J. Cordes, D. Degner, T. Schuhmann, S. Kasper

- **S-06-004**  
  A RCT to assess the benefits of Olanzapine and Amisulpride combination treatment (COMBINE): design and methods  
C. Schmidt-Kraepelin, Düsseldorf, Germany
<table>
<thead>
<tr>
<th>S-07</th>
<th>SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14.30 – 16.00 h</td>
</tr>
<tr>
<td></td>
<td>Loft A</td>
</tr>
<tr>
<td></td>
<td>Dimensional concepts of psychosis</td>
</tr>
<tr>
<td></td>
<td>Chairs: W. Strik, Bern, Switzerland</td>
</tr>
<tr>
<td></td>
<td>A. Heinz, Berlin, Germany</td>
</tr>
<tr>
<td>S-07-001</td>
<td>Dimensions of psychotic symptoms and brain physiology</td>
</tr>
<tr>
<td></td>
<td>W. Strik, Bern, Switzerland</td>
</tr>
<tr>
<td></td>
<td>S. Walther, A. Wopfner, K. Stegmayer, D. Hubl, H. Horn, T. Dierks</td>
</tr>
<tr>
<td>S-07-002</td>
<td>Thought and language disorders in psychosis</td>
</tr>
<tr>
<td></td>
<td>T. Kircher, Marburg, Germany</td>
</tr>
<tr>
<td>S-07-003</td>
<td>Dysfunctions of the motor system in schizophrenia</td>
</tr>
<tr>
<td></td>
<td>S. Walther, Bern, Switzerland</td>
</tr>
<tr>
<td>S-07-004</td>
<td>The limbic system and positive symptoms of schizophrenia</td>
</tr>
<tr>
<td></td>
<td>A. Heinz, Berlin, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-01</th>
<th>ORAL PRESENTATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14.30 – 16.00 h</td>
</tr>
<tr>
<td></td>
<td>Einstein Hall</td>
</tr>
<tr>
<td></td>
<td>Neurobiology</td>
</tr>
<tr>
<td></td>
<td>Chair: A. Papassotiropoulos, Basel, Switzerland</td>
</tr>
<tr>
<td>O-01-001</td>
<td>Deviations of levels of serum auto-antibodies (a-Ab) to the antigens of nervous tissue in patients with schizophrenia: confirmation of the mild encephalitis hypothesis</td>
</tr>
<tr>
<td></td>
<td>V. Orlova, Moscow, Russia</td>
</tr>
<tr>
<td></td>
<td>I. Mikhailova, V. Minutko, N. Eliseeva, J. Kretova</td>
</tr>
<tr>
<td>O-01-002</td>
<td>Evaluation of a potential endophenotype marker in schizophrenia: a blunted niacin response</td>
</tr>
<tr>
<td></td>
<td>J. Yao, Pittsburgh, USA</td>
</tr>
<tr>
<td></td>
<td>G. Dougherty, G. Haas, R. Condray, E. Messamore</td>
</tr>
<tr>
<td>O-01-003</td>
<td>The role of agmatine in pathogenesis of schizophrenia</td>
</tr>
<tr>
<td></td>
<td>T. Uzbay, Istanbul, Turkey</td>
</tr>
<tr>
<td></td>
<td>H. Kayir</td>
</tr>
<tr>
<td>O-01-004</td>
<td>Reduced striatal adenosine A(2A) receptor levels define a molecular subgroup in schizophrenia</td>
</tr>
<tr>
<td></td>
<td>M. Barrachina, L’Hospitalet de Llobregat, Spain</td>
</tr>
<tr>
<td></td>
<td>I. Villar-Menéndez, S. Díaz-Sánchez, M. Blanch, J. L. Albasanz, T. Pereira-Veiga, A. Manje, L. M. Planchat, I. Ferrer, M. Martín</td>
</tr>
<tr>
<td>O-01-005</td>
<td>Correlative multiscale volume microscopy study of white matter cell structures in post-mortem samples of human brain</td>
</tr>
<tr>
<td></td>
<td>V. Shklover, Skolkovo, Odintsovsky District, Russia</td>
</tr>
<tr>
<td></td>
<td>N. Uranova, V. Chelpanov, A. Lavrenyuk, P. Kazanski</td>
</tr>
<tr>
<td>O-01-006</td>
<td>Impact of chronic nicotine treatment on Hippocampal Oscillatory Activity in a G72/30 transgenic mouse model for schizophrenia</td>
</tr>
<tr>
<td></td>
<td>A. Lundt, Bonn, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>W-01</th>
<th>WORKSHOPS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14.30 – 18.00 h</td>
</tr>
<tr>
<td></td>
<td>Loft C</td>
</tr>
<tr>
<td></td>
<td>How to write manuscripts for publication in English language scientific journals</td>
</tr>
<tr>
<td></td>
<td>Chair: S. Hodgins, Montreal, Canada</td>
</tr>
</tbody>
</table>
### S-08 SYMPOSIA

**16.30 – 18.00 h Humboldt Hall**

**Biological pathways to psychosis: the role of stress**

*Chairs: D. Nordholm, Copenhagen, Denmark*

*S. Wood, Birmingham, United Kingdom*

<table>
<thead>
<tr>
<th>S-08-001</th>
<th>Pituitary volume, cortisol and stress in healthy controls, ultra high-risk subjects and first episode psychosis subjects</th>
</tr>
</thead>
</table>
|          | D. Nordholm, Copenhagen, Denmark  
|          | E. Rostrup, L. Randers, M. O. Nielsen, H. Emig-Norbak, V. Mondelli, P. Dazzan, M. Nordentoft, B. Glenthøj |

<table>
<thead>
<tr>
<th>S-08-002</th>
<th>The effect of stress and its biological mediators on the onset and clinical outcome of psychosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>V. Mondelli, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-08-003</th>
<th>The effect of stress on cortical thickness, surface area and subcortical brain volume in first episode psychosis over the first 12 weeks of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R. Reniers, Birmingham, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-08-004</th>
<th>Effect of pre-exposure to chronic social stress on HPA axis and neurotoxicity in animal models of schizophrenia</th>
</tr>
</thead>
</table>
|          | D. Inta, Mannheim, Germany  
|          | D. Filipovic, P. Gass |

### S-09 SYMPOSIA

**16.30 – 18.00 h Kleist Hall**

**Suicide prevention in schizophrenia**

*Chairs: D. Wasserman, Stockholm, Sweden*

*S. Galderisi, Naples, Italy*

<table>
<thead>
<tr>
<th>S-09-001</th>
<th>Epidemiology of suicide and attempted suicide in the population of schizophrenic patients</th>
</tr>
</thead>
</table>
|          | A. Schmidtke, Wuerzburg, Germany  
|          | D. Wasserman, B. Pfuhlmann, M. Sarchapione, J. Maloney |

<table>
<thead>
<tr>
<th>S-09-002</th>
<th>Psychotic symptoms as a risk marker for suicidal behaviour</th>
</tr>
</thead>
</table>
|          | I. Kelleher, Dublin, Ireland  

<table>
<thead>
<tr>
<th>S-09-003</th>
<th>Strategies and possibilities in suicide prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D. Wasserman, Stockholm, Sweden</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-09-004</th>
<th>Challenges in clinical practice: predicting, treating and rehabilitating suicidal schizophrenia patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Galderisi, Naples, Italy</td>
</tr>
</tbody>
</table>

### PL-02 PLENARY LECTURES

**18.15 – 19.00 h Humboldt Hall**

**Shifting paradigms for therapeutic discovery**

*Chair: W. Gaebel, Düsseldorf, Germany*

<table>
<thead>
<tr>
<th>PL-02-001</th>
<th>Shifting paradigms for therapeutic discovery</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>W. T. Carpenter Jr., Baltimore, USA</td>
</tr>
</tbody>
</table>

---

22
### S-10 SYMPOSIA

**16.30 – 18.00 h**  
**Loft A**

**Eye movement research: a window to cognitive impairments in schizophrenia?**

*Chairs: W. Wölwer, Düsseldorf, Germany  
M. Boucart, Lille, France*

| S-10-001 | Independence of smooth pursuit and visual scanpaths and a model of eye movement dysfunction in major mental illnesses  
P. Benson, Aberdeen, United Kingdom  
S. A. Beedie, E. Nouzová, D. St. Clair |
| S-10-002 | The relationship between visual exploration and action processing in schizophrenia  
M. Boucart, Lille, France |
| S-10-003 | Gaze behavior in early states of psychosis  
S. Ruhrmann, Cologne, Germany  
A. Nikolaides, S. Miess, R. Müller, J. Klosterkötter |
| S-10-004 | Concurrent assessment of eye movements and EEG in schizophrenia  
S. Strath, Düsseldorf, Germany  
K. Drusch, D. Kamp, W. Wölwer |

### S-11 SYMPOSIA

**16.30 – 18.00 h**  
**Einstein Hall**

**Microglia in schizophrenia**

*Chairs: S. Wolf, Berlin, Germany  
P. Falkai, Munich, Germany*

| S-11-001 | HLA-DR+ microglia are increased in paranoid schizophrenia versus residual schizophrenia: evidence from human postmortem studies  
J. Steiner, Magdeburg, Germany  
S. Busse, H.-G. Bernstein, B. Bogerts |
| S-11-002 | Immunohistochemical investigations of microglia in schizophrenia  
A. Schmitt, Munich, Germany  
T. Bayer, P. Falkai |
| S-11-003 | Microglia properties in schizophrenia  
A. Friebe, Bochum, Germany  
G. Juckel |
| S-11-004 | Epigenetic changes in microglia derived from an animal model for schizophrenia  
S. Wolf, Berlin, Germany  
D. Mattei |
S-12 SYMPOSIA
08.30 – 10.00 h Humboldt Hall
Negative symptoms – impact and therapeutic options
Chairs: N. Sartorius, Geneva, Switzerland
W. Gaebel, Düsseldorf, Germany

S-12-001
Negative symptoms in schizophrenia: prevalence and impact on functional outcome
S. Galderisi, Naples, Italy

S-12-002
Negative symptoms, culture and the stigma of schizophrenia
N. Sartorius, Geneva, Switzerland

S-12-003
Current therapeutical options and unmet needs in treating negative symptoms in schizophrenia
W. Gaebel, Düsseldorf, Germany

S-12-004
Future prospects in the treatment of schizophrenia negative symptoms
D. Bugarski-Kirola, Switzerland

S-13 SYMPOSIA
08.30 – 10.00 h Kleist Hall
Progression in brain tissue loss, antipsychotic medication, cognition and outcomes in schizophrenia – the Northern Finland 1966 Birth Cohort Study
Chairs: J. Miettunen, Oulu, Finland
M. Isohanni, Oulu, Finland

S-13-001
Outcomes of schizophrenia from a lifespan perspective – the Northern Finland 1966 Birth Cohort Study
M. Isohanni, Oulu, Finland
D. Cowling, P. Juola, J. Moilanen, A. Husa, M. Penttilä, S. Huhtaniska, J. Veijola, J. Miettunen, E. Jääskeläinen

S-13-002
Antipsychotic medication and longitudinal changes in brain volume in schizophrenia: meta-analysis and results from the Northern Finland 1966 Birth Cohort Study
J. Miettunen, Oulu, Finland
S. Huhtaniska, N. Hirvonen, J. Remes, G. Murray, J. Veijola, M. Isohanni, E. Jääskeläinen

S-13-003
Longitudinal association between antipsychotic medication and change of cognition in schizophrenia – the Northern Finland 1966 Birth Cohort Study
A. Husa, Oulu, Finland

S-13-004
Duration of untreated psychosis and outcomes and brain volume loss in schizophrenia – the Northern Finland 1966 Birth Cohort Study
M. Penttilä, Oulu, Finland
**S-14**

**SYMPOSIA**

**08.30 – 10.00 h**  
**Loft A**

**Translational genetics for psychiatric illnesses**

Organised by the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

*Chairs: W. Maier, Bonn, Germany  
T. Schulze, Göttingen, Germany*

---

**S-14-001**

**Genetic mouse models of relevance to schizophrenia: converging neurobiological mechanisms?**

J. A. Pratt, Glasgow, United Kingdom

---

**S-14-002**

**The path to translating genetics into clinical psychiatry: a realistic assessment**

T. Schulze, Göttingen, Germany

---

**S-14-003**

**Rat models for cognition and cognitive deficits**

D. Bartsch, Mannheim, Germany

---

**S-14-004**

**The genetic basis of human memory and its relevance for neuropsychiatric disorders**

A. Papassotriopulos, Basel, Switzerland

---

**0-02**

**ORAL PRESENTATIONS**

**08.30 – 10.00 h**  
**Einstein Hall**

**Neuropsychology**

*Chair: W. Wölwer, Düsseldorf, Germany*

---

**0-02-001**

**Social motor coordination in schizophrenia patients: a new clinical perspective**

D. Capdevielle, Montpellier, France


---

**0-02-002**

**To trust or not to trust: the dynamics of social interactions in early psychosis**

A.-K. Fett, Amsterdam, The Netherlands

S. S. Shergill, P. M. Gromann, D. W. Joyce, L. Krabbenbend

---

**0-02-003**

**Is the theory of mind deficit in schizophrenia explained by an impaired attention toward faces?**

P. Roux, Paris, France

B. Forgeot d’Arc, C. Passerieux, F. Ramus

---

**0-02-004**

**To see, or not to see: that is the question. The “Protection-Against-Schizophrenia” (PAS) model**

S. Landgraf, Regensburg, Germany

---

**0-02-005**

**Associations between metamemory and neurocognitive abilities in schizophrenia**

S. Eifler, Mannheim, Germany


---

**0-02-006**

**The relationship between stress and cognitive performance in real life environments in patients with schizophrenia**

B. Wright, London, United Kingdom

E. Peters, E. Kuipers, V. Kumari
### S-15 SYMPOSIA

**10.30 – 12.00 h**  
**Humboldt Hall**

**The future of psychopathology in the light of current neuroscience**

*Chairs: O. Gruber, Göttingen, Germany*
*W. Gaebel, Düsseldorf, Germany*

| S-15-001 | RDoC and the future classification of schizophrenia spectrum disorders  
B. N. Cuthbert, Bethesda, USA |
| S-15-002 | Modular psychopathology and symptom dimensions in schizophrenia  
W. Gaebel, Düsseldorf, Germany |
| S-15-003 | Neuroimaging of symptoms and endophenotypic brain dysfunctions in schizophrenia: psychopatho(physio)logy of the future?  
O. Gruber, Göttingen, Germany |
| S-15-004 | Symptom dimensions and brain systems: their roles for understanding and treatment of schizophrenia spectrum disorders  
W. Strik, Bern, Switzerland  
J. Kindler, P. Homann, A. Wopfner, K. Stegmayer, H. Horn, T. Dierks |

### S-16 SYMPOSIA

**10.30 – 12.00 h**  
**Kleist Hall**

**New approaches to cognitive behavior therapy for psychosis**

*Chairs: T. Kircher, Marburg, Germany*
*J. Klosterkötter, Cologne, Germany*

| S-16-001 | Cognitive biases as moderators and mediators of successful CBTp  
S. Mehl, Marburg, Germany |
| S-16-002 | Psychotherapy in subjects at high mental risk state  
A. Bechdolf, Berlin, Germany |
| S-16-003 | How does CBT effect the brain of patients with schizophrenia: a multicenter fMRI study  
A. Krug, Marburg, Germany |
| S-16-004 | Who benefits and why? Predictors of change and drop-out during cognitive behavioural therapy for psychosis  
T. Lincoln, Hamburg, Germany  
S. Mehl, S. Westermann, M. Ziegler, M.-L. Kesting, E. Luellmann, W. Rief |

### PL-03 PLENARY LECTURES

**12.15 – 13.00 h**  
**Humboldt Hall**

**Structure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric research**

*Chair: W. Maier, Bonn, Germany (tbc)*

| PL-03-001 | Structure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric research  
K. Zilles, Aachen, Germany |
**S-17** SYMPOSIA

10.30 – 12.00 h  Loft A

**Epigenetic dysregulation in schizophrenia**

*Chairs: P. Falkai, Munich, Germany*

* A. Fischer, Göttingen, Germany

**S-17-001**

Cognitive symptoms in schizophrenia – pharmacological aspects of a core symptom domain

*W. Fleischhacker, Innsbruck, Austria*

**S-17-002**

Molecular basis of epigenetic regulation

*A. Fischer, Göttingen, Germany*

**S-17-003**

hDACi for the treatment of schizophrenia – preclinical and clinical aspects

*A. Hasan, Munich, Germany*

**S-17-004**

Epigenetic therapies in oncology – clinical and safety aspects

*M. Bitzer, Tübingen, Germany*

---

**O-03** ORAL PRESENTATIONS

10.30 – 12.00 h  Einstein Hall

**Functional neuroimaging**

*Chair: A. Aleman, Groningen, The Netherlands*

**O-03-001**

Phenotyping schizophrenia by multi-modal brain imaging

*U. Schall, Collagahn, Australia*

**O-03-002**

Working memory dependent prefrontal-parietal connectivity and model-based diagnostic classification in schizophrenia

*L. Deserno, Berlin, Germany*

*K. H. Brodersen, Z. Lin, W. D. Penny, A. Heinz, K. E. Stephan, F. Schlagenhauf*

**O-03-003**

Shared brain phenotypes for working memory dysfunction among schizophrenia and bipolar disorder

*M. Green, Sydney, Australia*

*Y. Quide, A. Shepherd, R. Morris, J. Rowland, P. Mitchell, V. Carr*

**O-03-004**

Alterations in the theory of mind network in unaffected first-degree relatives of patients with schizophrenia

*H. Walter, Berlin, Germany*

*S. Mohnke, S. Erk, N. Seiferth, O. Grimm, L. Haddad, K. Schnell, M. Nöthen, A. Heinz, A. Meyer-Lindenberg*

**O-03-005**

Reduced activation in nucleus accumbens and ventral tegmental area during probabilistic decision-making in schizophrenia

*F. Rausch, Mannheim, Germany*


**O-03-006**

Abnormal delta oscillatory activity during acute psychotic episode in schizophrenia: a MEG study

*J. Tarrago, Barcelona, Spain*

*R. Novak, C. Alanso, O. Pino, E. Rojo*
**P-05-001**  
Glutamate concentrations and performance during operant conditioning in schizophrenia  
T. Gleich, Berlin, Germany  
R. Böhme, L. Deserno, A. Pankow, J. Gallinat, A. Heinz, F. Schlagenhauf

**P-05-002**  
Altered adhesion and microfilament organization in neuronal precursors of schizophrenia patients: reversion by melatonin  
G. Benítez-King, México-City, Mexico  

**P-05-003**  
Neuropathological finding of frontal cortex of animal model and postmortem human brain of schizophrenia  
S. Iritani, Nagoya, Japan  
H. Sekiguchi, C. Habuchi, K. Umeda, Y. Torii, M. Miyata, K. Fujita, N. Ozaki

**P-05-004**  
Molecular mechanisms of visual adaptation: a role for the DTNBP1 (Dysbindin) schizophrenia risk gene in visual short-term plasticity  
G. Andrade, Bronx, New York, USA  
J. Butler, B. Abrahams, J. Foxe

**P-05-005**  
Expression of DISC1 in the development of the white matter of rats  
C. Li, Chongqing, People’s Republic of China  
L. Xiao, S. Liu, M. Wei

**P-05-006**  
Role of CB1 receptor and endocannabinoids on cortico-striatal connectivity of psychosocially stressed mice  
U. Havemann-Reinecke, Göttingen, Germany

**P-05-008**  
Concordance and heritability in schizophrenia, register-based data from a Danish twin study  
R. Hilker, Glostrup, Denmark  
M. Nordentoft, D. Helenius, B. Glenthøj

**P-05-009**  
Acute intermittent porphyria and cycloid psychosis  
I. Daey Ouwens, Venray, The Netherlands

**P-05-010**  
Kallmann syndrome and schizophrenia: is there a relationship?  
W. Verhoeven, Venray, The Netherlands  
J. Egger, J. Hovens, N. De Leeuw, L. Hoeftsloot

**P-05-011**  
Routine screening for copy number variations in schizophrenia-spectrum disorders: relevant to clinical practice?  
W. Verhoeven, Venray, The Netherlands  
N. van de Kerkhof, I. Feenstra, F. van der Heijden, N. de Leeuw, J. Egger, G. Stöber
P-06-001
Altered reinforcement learning and working memory in psychosis
F. Schlagenhauf, Berlin, Germany

P-06-002
Reinforcement learning in an uncertain environment: behavioral and neural correlates in schizophrenia patients and healthy participants with delusional experiences
R. Boehme, Berlin, Germany

P-06-003
Model-free and model-based control in reinforcement learning: relation to dopamine synthesis and implications for schizophrenia
L. Deserno, Berlin, Germany
R. Böhm, A. Wilitzki, R. Buchert, Q. Huys, S. Florian

P-06-004
Neural correlates of action and expected value during the anticipation of monetary reward
Y. Fukuda, Berlin, Germany
L. Deserno, S. Koch, F. Schlagenhauf

P-06-005
Aberrant brain reward response in siblings of patients with psychosis during trust-related behaviour
P. Gromann, Amsterdam, The Netherlands
S. Shergill, L. de Haan, D. Meewis, A.-K. Fett, L. Krabbendam

P-06-006
Improvement of brain reward abnormalities related to Dopamine D2/D3 receptor blockade – a study in antipsychotic-naïve first-episode schizophrenia patients
S. Wulff, Glostrup, Denmark
M. Ø. Nielsen, E. Rostrup, B. Y. Glenthøj

P-06-007
Altered default mode network activity in schizophrenia patients
A. Pankow, Berlin, Germany

P-06-008
Self-reference processing in schizophrenia and psychotic experiences – an fMRI study
T. Katthagen, Berlin, Germany
A. Pankow, L. Deseno, M. Gaebler, A. Heinz, F. Schlagenhauf

P-06-009
Brief monocular deprivation as an assay of short-term visual sensory plasticity in schizophrenia – “the binocular effect”
J. Foxe, Bronx, USA
S. Yeap, V. Leavitt

P-06-010
Obsessive-compulsive symptoms in schizophrenia are associated with more activation of the orbito-frontal cortex
F. Schirmbeck, Mannheim, Germany
D. Mier, C. Esslinger, F. Rausch, S. Eifler, S. Englisch, A. Meyer-Lindenberg, P. Kirsch, M. Zink
P-07 – 14.30 h
Foyer
Research methods and health service research
Chair: to be announced

P-07-002
The early recognition inventory ERIraos detects at risk mental states of psychosis with high sensitivity
F. Rausch, Mannheim, Germany
S. Eifler, A. Esser, C. Esslinger, F. Schirmbeck, A. Meyer-Lindenberg, M. Zink

P-07-003
Assessment of prodromal symptoms in incipient psychotic disorders: reliability and validity measures of the Early Recognition Inventory-Spanish Version (ERIraos-SV)
S. Ochoa, Sant Boi de Llobregat, Spain

P-07-004
"It was easier than dealing with a pen and paper...": exploring the usability of electronic devices for completion of Clinical Outcome Assessments (COAs) in schizophrenia
C. Tolley, Bollington, UK
D. Rofail, A. Gater

P-07-005
When does “Yes” mean “Yes”: is parental consent a necessary component of obtaining informed consent from minors in Canada’s indigenous context
C. Cheng, Thunder Bay, Canada
J. Fogolin, M. Katt, S. Nadin, P. Braunberger, J. B. Minore, C. S. Dewa

P-07-007
Changing attitude towards schizophrenia by psychiatric training of medical students
F. Lang, Guenzburg, Germany
M. Kösters, S. Lang, T. Becker, M. Jäger

P-07-008
Assessment on the impact of financial crisis on the access to mental health services in Greece
E. Neroutsos, Elefsina-Athens, Greece
A. Pachi, M. Fiste, E. Kontomina, E. Bisbiki, N. Lytra

P-07-009
First Spanish virtual community for people who hear voices
M. J. Escarti Fabra, Valencia, Spain
E. Lorente Rovira, A. Luengo Martín, E. Aguilar, J. Sanjuán Arias

P-07-010
State and problems of psychiatric care in Kazakhstan (focus on schizophrenia)
S. Nurmagambetova, Almaty, Kazakhstan
M. Assimov
P-08-001
Cognitive impairments are linearly related to psychometric risk for schizophrenia-spectrum disorders
S. Giakoumaki, Rethymno, Greece
P. Roussos, C. Zouraraki, P. Bitsios

P-08-002
Is the tendency to extract meaning from auditory noise associated with schizotypy?
S. Morton, Dunedin, New Zealand
M. Nicolson, R. J. Linscott

P-08-003
Schizotypal traits in a community sample: characteristics and neuropsychological correlates
M. Tesse, London, United Kingdom

P-08-004
Schizotypal traits in a non-clinical population-based sample: characteristics and neuropsychological performance profiles
M. Tesse, London, United Kingdom

P-08-005
Neurocognitive performance in treatment-resistant and non-treatment-resistant schizophrenia
V. Anderson, Auckland, New Zealand
M. Mcllwain, C. McNabb, R. Kydd, B. Russell

P-08-006
Cognitive functioning in individuals aged >65 years with ‘very-late-onset schizophrenia-like-psychosis’ (VLOSPL), chronic schizophrenia and late-onset psychotic depression
S. Simpson, The Ponds, Australia
R. Langdon, J. Batchelor, A. Falcon, S. Tyagi

P-08-007
A comprehensive neuropsychological study of individuals with very-late-onset schizophrenia-like-psychosis
S. Simpson, The Ponds, Australia
R. Langdon, J. Batchelor, A. Falcon, S. Tyagi

P-08-008
The relationship between noise-induced stress and cognitive performance in patients with schizophrenia
B. Wright, London, United Kingdom
E. Peters, E. Kuipers, V. Kumari

P-08-009
The MATRICS Consensus Cognitive Battery (MCCB) in Norway: associations with IQ, clinical and occupational measures
J. Lystad, Oslo, Norway
E. Falkum, H. Bull, C. Mohn, B. Rishovd Rund, T. Ueland

P-08-010
The relation between insight and use of feedback on the Wisconsin Card Sorting Test in patients with schizophrenia
A. de Vos, Assen, The Netherlands
M. Pijnenborg, A. Aleman, L. van der Meer

P-08-011
Influence of gender on the primacy and recency effect in patients with a first-episode psychosis and schizophrenia patients
E. Huerta-Ramos, Sant Boi de Llobregat, Spain
A. Butjosa Molines, C. Núñez Leánez, J. Usall i Rudié, A. Barajas Vélez, A. Foix Sanjuan, M. Dolz Abadia, S. Ochoa Güerre

P-08-013
Relation between jumping to conclusions (JTC) and neuropsychological performance
S. Ochoa, Sant Boi de Llobregat, Spain
P-09-001
Sexual adverse effects and antipsychotic-induced hyperprolactinemia: a cross-sectional study
J. Usall, Sant Boi de Llobregat, Spain
R. Cambra, E. Rubio-Abadal, G. Saenz Navarrete, B. Arranz, N. del Cacho, R. Iniesta, M. Roca, V. Barneda

P-09-002
Sexual dysfunction in schizophrenic and schizoaffective patients treated with antipsychotics
M. Del Carmen García Mahía, A Coruña, Spain
M. Vidal Millares, E. Roman Fernandez

P-09-003
Psychiatric and non-psychiatric comorbidity in schizophrenic patients treated with antipsychotics
M. Del Carmen García Mahía, A Coruña, Spain
M. Vidal Millares, J. A. Amado García

P-09-004
Comparative assessment of the social performances for schizophrenic patients treated with long acting antipsychotics
M. C. Pirlog, Craiova, Romania
I. Marinescu, D. Marinescu

P-09-005
Antipsychotics and antidepressants and their associations with suicidal ideation – the Northern Finland Birth Cohort 1966 study
I. Rissanen, Oulu, Finland
E. Jääskeläinen, M. Isohanni, H. Koponen, M. Joukamaa, A. Alarääsänen, J. Miettunen

P-09-006
Involuntary hospitalization and the course of medication adherence, treatment engagement and perception of coercion
S. Jaeger, Ravensburg, Germany

P-09-007
Long-term effects of prefrontal rTMS on cognitive functioning in schizophrenia
C. Kos, Groningen, The Netherlands
J. Dlabac-de Lange, L. Bais, R. Kneegtering, A. Aleman

P-09-008
Trends in the administration of electroconvulsive therapy for schizophrenia in Colombia. Descriptive study and literature review
G. Oviedo, Bogotá, Colombia

P-09-009
Sleep prolongation may decrease level of self-reported sleepiness but not slow wave activity in electroencephalogram (EEG) in patients with schizophrenia
M. Jarema, Warsaw, Poland
L. Okruszek, A. Wichniak, A. Wierzbicka, E. Wali-nowska, K. Czesak, I. Musinska, T. Jakubczyk, W. Jernajczyk M.D.

P-09-010
Can work history at baseline predict work behavior within the first four weeks of vocational rehabilitation?
H. Bull, Oslo, Norway
T. Ueland, J. Ullevoldsæter Lystad, E. Falkum
From Therapy to Prevention

**SELECTION OF LECTURES**

- **What can Psychiatry contribute to the understanding of extreme violence?**
  Speaker: Ulrik Malt (Oslo, Norway)

- **Mental Health of European youth and scientific evidence for the suicide treatment and prevention**
  Speaker: Danuta Wasserman (Stockholm, Sweden)

- **Future of psychiatric services in the 21st century**
  Speaker: Dinesh Bhugra (London, United Kingdom)

- **Mental disorders and their care through history in Egypt**
  Speaker: Tarek A. Okasha (Kairo, Egypt)

- **Psychiatric Diagnosis: its past, present, and future**
  Speaker: Allen J. Frances (Coronado, USA)

- **CME certified**

- **English programme track**
S-22 SYMPOSIA
14.30 – 16.00 h Humboldt Hall
From structure to functioning: neurobiological candidates for the prediction of psychoses
Chairs: S. Ruhrmann, Cologne, Germany
S. Wood, Birmingham, United Kingdom

S-22-001
The contribution of structural brain imaging to the prediction of psychoses
N. Koutsouleris, Munich, Germany

S-22-002
The contribution of MR spectroscopy to the prediction of psychoses
S. Wood, Birmingham, United Kingdom

S-22-003
The contribution of functional imaging to the prediction of psychoses
S. Borgwardt, Basel, Switzerland

S-22-004
Contributions of cognitive neurophysiology to prediction of psychotic disorders
S. Ruhrmann, Cologne, Germany
R. Mueller, M. Bodatsch, J. Klosterkoetter

S-19 SYMPOSIA
14.30 – 16.00 h Kleist Hall
Should continuous antipsychotic medication be recommended after first episode psychosis?
Chairs: M. Nordentoft, Copenhagen, Denmark
L. Wunderink, Groningen, The Netherlands

S-19-001
Remission of psychotic symptoms and antipsychotic medication – long term follow-up of first episode patients included in the TIPS project
I. Melle, Haslum, Norway
J. I. Røssberg, W. T. Velden Hegelstad, J. H. Evensen,

S-19-002
A focus on poor physical health in psychosis: from animal data to the long-term follow-up of first episode patients from the AESOP study
V. Mondelli, London, United Kingdom
P. Dazzan

S-19-003
Remission of antipsychotic medication and remission of psychotic symptoms – long term follow-up of first episode patients included in the OPUS trial
M. Nordentoft, Copenhagen, Denmark
S. Austin, O. Mors

S-19-004
Recovery in remitted first episode psychosis at 7-years of follow-up of an early dose-reduction/discontinuation or maintenance treatment strategy
L. Wunderink, Groningen, The Netherlands
D. Wiersma, S. Sytema, F. Nienhuis
### S-20 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Loft A</td>
<td>The role of neuroinflammation in schizophrenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: A. J. Tanra, Makassar, Indonesia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Ohgidani, Fukuoka, Japan</td>
</tr>
</tbody>
</table>

#### S-20-001
Antipsychotics and minocycline as a possible modulator of microglial inflammatory/oxidative stress response in schizophrenia
M. Ohgidani, Fukuoka, Japan
T. Kato

#### S-20-002
Immature dentate gyrus and mild chronic inflammation: candidate endophenotype of neuropsychiatric disorders
T. Miyakawa, Toyoake, Japan

#### S-20-003
Low dose of Dextromethorphan may benefit in schizophrenia treatment
R.-B. Lu, Tainan City, Taiwan

#### S-20-004
The effects of minocycline on microglial cells activation in the dentate gyrus of Gunn rat: a possible animal model of schizophrenia
A. J. Tanra, Makassar, Indonesia

### S-21 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Einstein Hall</td>
<td>Experimental psychopathology of psychosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: M. Voss, Berlin, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Uhlhaas, Glasgow, United Kingdom</td>
</tr>
</tbody>
</table>

#### S-21-001
Delusions and the role of beliefs in perceptual inference
P. Sterzer, Berlin, Germany

#### S-21-002
Psychophysical and neurochemical aspects of context perception in schizophrenia
J. Terock, Luebeck, Germany
B. Zurowski

#### S-21-003
Disturbances in the sense of agency in schizophrenia
M. Voss, Berlin, Germany

#### S-21-004
High-frequency oscillations in schizophrenia: a translational perspective
P. Uhlhaas, Glasgow, United Kingdom

### W-02 WORKSHOPS

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 18.00 h</td>
<td>Loft C</td>
<td>How to apply for EU funding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: I. Zwoch, Bonn, Germany</td>
</tr>
</tbody>
</table>
### S-18 SYMPOSIA

<table>
<thead>
<tr>
<th>16.30 – 18.00 h Humboldt Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perspectives in schizophrenia research: emerging research issues</td>
</tr>
<tr>
<td>Organised by the European Scientific Association on Schizophrenia and other Psychosis (ESAS)</td>
</tr>
</tbody>
</table>
| Chairs: W. Gaebel, Düsseldorf, Germany  
S. Galderisi, Naples, Italy |

#### S-18-001
Emerging research issues in biological and translational research  
*P. Falkai, Munich, Germany/W. Maier, Bonn, Germany*

#### S-18-002
Emerging research issues concerning drug and other somatic treatments  
*H.-J. Möller, Munich, Germany*

#### S-18-003
Emerging research issues concerning psycho-social interventions  
*W. Rössler, Zurich, Switzerland*

#### S-18-004
Emerging research issues toward recovery: the case of negative and cognitive symptoms  
*S. Galderisi, Naples, Italy*

### S-23 SYMPOSIA

<table>
<thead>
<tr>
<th>16.30 – 18.00 h Kleist Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implementation of early intervention services for young people with first episode psychosis: rationale, evidence and practical experiences from Europe</td>
</tr>
</tbody>
</table>
| Chairs: A. Bechdolf, Berlin, Germany  
M. Birchwood, Birmingham, United Kingdom |

#### S-23-001
Why do we need specialized early intervention in first episode psychosis?  
*A. Bechdolf, Berlin, Germany*

#### S-23-002
The early intervention service reform in the UK: outcomes and the next wave of reform  
*M. Birchwood, Birmingham, United Kingdom*

#### S-23-003
The EPPIC follow-up study: baseline clinical characteristics and longer-term outcome of first-episode schizophrenia  
*G. P. Amminger, Parkville, Australia*

#### S-23-004
Implementation of early intervention services in Denmark – from research to practice  
*M. Nordentoft, Copenhagen, Denmark*
### S-24 SYMPOSIA
16.30 – 18.00 h  Loft A

**Studies using structural and functional neuroimaging to advance understanding of schizophrenia**

*Chairs: S. Hodgins, Montreal, Canada
B. Schiffer, Bochum, Germany*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| S-24-001 | Altered contextual modulation of primary visual cortex responses in schizophrenia | P. Sterzer, Berlin, Germany
K. Seymour |
| S-24-002 | Mentalizing abilities and their neural underpinnings in different types of offenders with schizophrenia | B. Schiffer, Bochum, Germany |
| S-24-003 | Animacy experience and mentalizing in schizophrenic patients who engage in violent offending | C. Pawliczek, Aachen, Germany
B. Schiffer |
| S-24-004 | Grey matter density in different types of violent offenders with schizophrenia | S. Hodgins, Montreal, Canada
B. Schiffer |

### O-04 ORAL PRESENTATIONS
16.30 – 18.00 h  Einstein Hall

**Comorbidity**

*Chair: N. Sartorius, Geneva, Switzerland*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-04-001</td>
<td>The role of striatal dopamine in co-morbid addictive states in schizophrenia – revisiting the „self-medication hypothesis”</td>
<td>A. G. Awad, Toronto, Canada</td>
</tr>
</tbody>
</table>
| O-04-002 | The role of substance abuse in prediction of long-term outcome of schizophrenia – systematic review and meta-analysis | J. Miettunen, Oulu, Finland
K. Kasurinen, N. Hirvonen, E. Oinas, J. Käkelä, E. Jääskeläinen, A. Alaräsänä |
| O-04-003 | Is there a relation between reward-disturbances and weight gain caused by antipsychotic medication in patients with schizophrenia? | M. Nielsen, Roskilde, Denmark
S. Wulff, B. Broberg, E. Rostrup, B. Glenthøj |
| O-04-004 | Association between cognitive deficits and obsessive-compulsive symptoms in patients with psychosis and un-affected siblings: a 3 year follow-up | F. Schirmbeck, Mannheim, Germany
M. Swets, M. Zink, R. Kahn, J. van Os, R. Bruggeman, W. Cahn, A. Bartels, C. J. Meijer, I. Myin-Germeys, L. de Haan |
| O-04-005 | Dissociation and social cognition in schizophrenia spectrum disorder | S. Renard, Groningen, The Netherlands
M. Pijnenborg, P. Lysaker |
| O-04-006 | Multimorbidity in psychotic disorders and their unaffected siblings: an epidemiological perspective | M. F. Khan, Groningen, The Netherlands
S-25 SYMPOSIA
18.15 – 19.45 h Humboldt Hall
Nosology in the schizophrenic psychoses: new insight from functional neuroimaging and genetics
Chairs: B. Pfuhlmann, Wuerzburg, Germany
J. Foucher, Strasbourg, France

S-25-001
Cycloid psychosis in a Dutch psychiatric teaching hospital: relevance for diagnosis, treatment and prognosis
W. Verhoeven, Venray, The Netherlands
N. van de Kerkhof, F. Van der Heijden, M. Schneider, G. Stöber

S-25-002
Genome-wide search for de novo copy-number variations (CNVs) in cycloid psychoses and chronic schizophrenic psychoses with phenotype correlation
M. Gawlik, Cardiff, United Kingdom
G. Kirov, E. Rees, L. Georgieva, G. Stoeber

S-25-003
Functional integration in cycloid psychosis and affect-laden paraphrenia: a double dissociation within the DSM-IV diagnosis of schizophrenia
J. Foucher, Strasbourg, France

S-25-004
New genetic loci for periodic catatonia on chromosome 7p14.1 and 19p12 in a genome-wide association study with pooled DNA
G. Stöber, Wuerzburg, Germany
D. Schanze, A. B. Ekici, B. Pfuhlmann, A. Reis

S-26 SYMPOSIA
18.15 – 19.45 h Kleist Hall
The consequences of childhood trauma in psychotic disorders
Chairs: I. Melle, Haslum, Norway
M. Aas, Oslo, Norway

S-26-001
Childhood trauma and clinical features in bipolar disorder
I. Melle, Haslum, Norway
B. Etain, M. Aas, O. A. Andreassen, F. Bellivier, C. Henry

S-26-002
Biological pathways between childhood trauma and psychosis onset
V. Mondelli, London, United Kingdom

S-26-003
Trauma and neglect in first episode psychosis: preliminary results 2
A. M. Trauelsen, Copenhagen, Denmark

S-26-004
Interactions between BDNF Val66Met, childhood adverse events and brain volume abnormalities in schizophrenia and bipolar disorders
M. Aas, Oslo, Norway
U. K. Haukvik, S. Djurovic, Ø. Bergmann, S. Lorentzen, O. A. Andreassen, I. Agartz, I. Melle
S-27 SYMPOSIA
18.15 – 19.45 h Loft A
Progress in neuropathological post-mortem findings in schizophrenia
Chairs: A. Schmitt, Munich, Germany
J. Steiner, Magdeburg, Germany

S-27-001
Neuropathological assessment of autopsy cases with schizophrenia – recommendations of the Brain Net Europe Consortium
T. Arzberger, Munich, Germany

S-27-002
Histological and gene expression studies of the hippocampus in schizophrenia
A. Schmitt, Munich, Germany
H.-G. Bernstein, J. Steiner, C. Schmitz, B. Bogerts, M. Rossner, P. Falkai

S-27-003
Oligodendrocytes in schizophrenia
J. Steiner, Magdeburg, Germany
H.-G. Bernstein, B. Bogerts

S-27-004
Applying proteomics to schizophrenia post-mortem brain tissue
D. Martins-de-Souza, Munich, Germany

O-05 ORAL PRESENTATIONS
18.15 – 19.45 h Einstein Hall
Course and outcome
Chair: V. W. Larach, Santiago, Chile

O-05-001
Gender differences in first episode psychosis at five-year follow-up – two different courses of disease?
A. Thorup, Copenhagen, Denmark
N. Albert, B. Mette, L. Petersen, P. Jeppesen, P. Le Quarck, M. Nordentoft

O-05-002
Association of familial risk to social, occupational and global outcome in schizophrenia – systematic review and meta-analysis
J. Käkelä, Oulu, Finland
E. Oinas, E. Jääskeläinen, J. Miettunen

O-05-003
The characteristics of self-experiences and the quality of life in persons with schizophrenia and those after spinal-cord injury
B. Horvat, Velika Polana, Slovenia

O-05-004
Quality of life and internalized stigma in patients with schizophrenia: examining the influence of clinical diagnostic and treatment setting
S. Oliveira, Lisboa, Portugal
F. Esteves

O-05-006
Helping people with psychotic disorders back to work – the JUMP study
E. Falkum, Oslo, Norway
J. Lystad, H. Bull, S. Evensen, T. Ueland
### S-28 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.00 h</td>
<td>Humboldt Hall</td>
<td>The high risk state for psychosis</td>
<td>J. Klosterkötter, Cologne, Germany P. Fusar-Poli, London, United Kingdom</td>
</tr>
<tr>
<td>S-28-001</td>
<td></td>
<td>The ultra high risk approach – current state and future directions</td>
<td>P. Fusar-Poli, London, United Kingdom A. Yung</td>
</tr>
<tr>
<td>S-28-002</td>
<td></td>
<td>The basic symptom approach for identifying individuals at high risk</td>
<td>J. Klosterkötter, Cologne, Germany</td>
</tr>
<tr>
<td>S-28-003</td>
<td></td>
<td>The impact of social functioning and Axis-1 diagnoses</td>
<td>R. K. R. Salokangas, Turku, Finland</td>
</tr>
<tr>
<td>S-28-004</td>
<td></td>
<td>Searching for neuroimaging markers of the high-risk state of psychosis</td>
<td>S. Borgwardt, Basel, Switzerland</td>
</tr>
</tbody>
</table>

### S-29 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.00 h</td>
<td>Kleist Hall</td>
<td>The role of oligodendrocytes in schizophrenia: disease-inherent versus treatment-induced abnormalities</td>
<td>J. Steiner, Magdeburg, Germany N. Uranova, Moscow, Russia</td>
</tr>
<tr>
<td>S-29-001</td>
<td></td>
<td>Ultrastructural alterations of myelinated fibers and oligodendrocytes in schizophrenia</td>
<td>N. Uranova, Moscow, Russia V. Shklover, O. Vikhreva, V. Rachmanova, D. Orlovs-kaya, P. Kazanskiy, V. Chelpanov</td>
</tr>
<tr>
<td>S-29-002</td>
<td></td>
<td>Oligodendrocyte dysfunction in schizophrenia by proteomics</td>
<td>D. Martins-de-Souza, Munich, Germany</td>
</tr>
<tr>
<td>S-29-003</td>
<td></td>
<td>Animal experiment data regarding the effect of antipsychotic drugs on oligodendrocyte turnover</td>
<td>L. Xiao, Chongqing, People’s Republic of China H. Wang, J. Niu, H. Wang</td>
</tr>
<tr>
<td>S-29-004</td>
<td></td>
<td>Protective role of haloperidol and clozapine on energy-deprived oligodendrocytes in culture</td>
<td>J. Steiner, Magdeburg, Germany H.-G. Bernstein, B. Bogerts, G. Keilhoff</td>
</tr>
</tbody>
</table>
08.30 – 10.00 h  Loft A

**S-30**

**Symposia**

**Oscillations and synchrony in cortical networks in schizophrenia**
Jointly organised by the Asian Network for Schizophrenia Research (ANSR) and the European Scientific Association on Schizophrenia and other Psychosis (ESAS)

**Chairs:** J. S. Kwon, Seoul, Republic of Korea  
S. Ruhrmann, Cologne, Germany

---

**S-30-001**

Oscillations and synchrony in animal models of schizophrenia
T. Sigurdsson, Frankfurt am Main, Germany

---

**S-30-002**

High-frequency oscillations in schizophrenia: perspectives from MEG
P. Uhlhaas, Glasgow, United Kingdom

---

**S-30-003**

Altered oscillatory activity in the alpha-theta frequency range in schizophrenia patients
R. Müller, Cologne, Germany  
S. Ruhrmann

---

**S-30-004**

Abnormal oscillations and synchrony of MEG in ultra-high risk subjects for psychosis
J. S. Kwon, Seoul, Republic of Korea

08.30 – 10.00 h  Einstein Hall

**O-06**

**Oral Presentations**

**Treatment**

Chair: A. G. Awad, Toronto, Canada

---

**O-06-001**

Waiting for godot
D. Goel, Invercargill, New Zealand

---

**O-06-002**

Preliminary results of the Neuroleptic Strategy Study (NeSSy)
M. Heinze, Ruedersdorf, Germany  

---

**O-06-003**

Working out first-episode schizophrenia: neuroanatomical, cognitive and clinical changes following an aerobic exercise intervention
P. Ward, Liverpool, Australia  

---

**O-06-005**

Does one program look like the other? A systematic review of practices to measure fidelity to early psychosis intervention standards
C. Cheng, Thunder Bay, Canada  
A. Selick, J. Durbin, S. Moss

---

**O-06-006**

Effectiveness of a community-based early intervention program for psychosis: baseline characteristics and three-month follow-up
J. Barglow, New York, USA  
T. Dole, M. Birnbaum

---

**O-06-007**

Relapses during long-term hospitalization of people suffering from schizophrenia
G. Bogojevic, Belgrade, Serbia  
D. Zigmund, L. Ziravac, U. Pavic
**S-31 SYMPOSIA**

10.30 – 12.00 h Humboldt Hall

**Indicated prevention of psychosis**

*Chairs: J. Klosterkötter, Cologne, Germany*

*M. Birchwood, Birmingham, United Kingdom*

**S-31-001**

*Interventions in people at high risk of psychosis: results of randomized controlled trials*

*A. Bechdolf, Berlin, Germany*

**S-31-002**

*Omega-3 fatty acids for indicated prevention: treatment results and pathomechanisms*

*G. P. Amminger, Parkville, Australia*

*M. S. Harris, P. D. McGorry, L. P. Henry*

**S-31-003**

*MindNet: a new model of implementation of early intervention services*

*M. Lambert, Hamburg, Germany*

**S-31-004**

*From risk factors to resilience: perspectives for the prevention of mental disorders*

*S. Ruhrmann, Cologne, Germany*

---

**W-03 WORKSHOPS**

10.30 – 12.00 h Kleist Hall

**International perspectives of quality of care and integration of persons with schizophrenia**

*Jointly organised by the WPA sections on schizophrenia and quality assurance*

*Chairs: A. Javed, Nuneaton, United Kingdom*

*W. Gaebel, Düsseldorf, Germany*

**W-03-001**

*Long term outcome of schizophrenia in developing and developed countries*

*N. Sartorius, Geneva, Switzerland*

**W-03-002**

*Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle income countries*

*A. Lora, Lecco, Italy*

**W-03-003**

*The developing countries view on ensuring quality of care*

*A. Javed, Nuneaton, United Kingdom*

**W-03-004**

*Strategy for management of first psychotic episode supported by state law guarantees in a middle-income country*

*V. W. Larach, Santiago, Chile*

**W-03-005**

*Towards a global definition of quality of mental health services – lessons learned from developing a respective EPA guidance*

*W. Gaebel, Düsseldorf, Germany*
**S-32 SYMPOSIA**

10.30 – 12.00 h Loft A

Single symptom approaches in schizophrenia: neuronal correlates of auditory hallucinations and language related symptoms

Chairs: J. Gallinat, Berlin, Germany
T. Dierks, Bern, Switzerland

---

**S-32-001**
Auditory hallucinations and the language system
T. Dierks, Bern, Switzerland

**S-32-002**
Hearing voices as a phenomenon of dysconnectivity?
C. Mulert, Hamburg, Germany

**S-32-003**
Auditory hallucinations and ego-disturbances: imaging of dysfunctional brain networks
J. Gallinat, Berlin, Germany

**S-32-004**
Non-invasive brain stimulation for the treatment of schizophrenia: neurobiological and clinical aspects
A. Hasan, Munich, Germany

---

**S-33 SYMPOSIA**

10.30 – 12.00 h Einstein Hall

The schizophrenia motor dimension: clinical relevance and neurobiology

Chairs: S. Walther, Bern, Switzerland
M. Morrens, Antwerp, Belgium

---

**S-33-001**
Parsing the components of psychomotor functioning in schizophrenia
M. Morrens, Antwerp, Belgium

**S-33-002**
Motor signs in individuals at risk of schizophrenia
P. N. van Harten, Maastricht, The Netherlands

**S-33-003**
Clinical and cerebral correlates of neurological soft signs in schizophrenia
J. Schröder, Heidelberg, Germany

**S-33-004**
Dysfunctional subcortico-cortical interactions in the motor loop as probable cause for hypokinesia in schizophrenia
S. Walther, Bern, Switzerland

---

**PL-04 PLENARY LECTURES**

12.15 – 13.00 h Humboldt Hall

Twenty years of early intervention in psychosis: how critical is the critical period hypothesis?

Chair: J. Klosterkötter, Cologne, Germany

---

**PL-04-001**
Twenty years of early intervention in psychosis: how critical is the critical period hypothesis?
M. Birchwood, Birmingham, United Kingdom
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-10-001</td>
<td>Metacognitive training for patients with schizophrenia: preliminary evidence for a targeted single-module program</td>
<td>R. Balzan, Adelaide, Australia P. Delfabbro, C. Galletly, T. Woodward</td>
</tr>
<tr>
<td>P-10-002</td>
<td>Cognitive remediation therapy in schizophrenia</td>
<td>M. Fiste, Chaidari-Athens, Greece M. Papagathaggelou, N. Lytra, E. Thermou, E. Neroutsos</td>
</tr>
<tr>
<td>P-10-003</td>
<td>Does the integrated psychological therapy improve neurocognition and social-functioning in patients with schizophrenia?</td>
<td>A. Taksal, Bangalore, India P. Sudhir, K. Kumar, J. Thirthalli, D. Vishwanath</td>
</tr>
<tr>
<td>P-10-004</td>
<td>Rehabilitation of communicative abilities in schizophrenic patients through the cognitive pragmatics treatment: a pilot study</td>
<td>F. M. Bosco, Turin, Italy I. Gabbatore, E. Geda, P. Gastaldo, F. Cauda, R. Angeleri, E. Pirro, T. Costa, S. Duca, B. G. Bara, K. Sacco</td>
</tr>
<tr>
<td>P-10-005</td>
<td>Cognitive-behavioral therapy and negative symptoms of schizophrenia</td>
<td>M. Fiste, Chaidari-Athens, Greece E. Neroutsos, N. Lytra, G. Triantafyllou, E. Thermou</td>
</tr>
<tr>
<td>P-10-006</td>
<td>Effectiveness of group therapy aimed at overcoming schizophrenia</td>
<td>A. M. Rojas Rivera, San Antonio, Chile</td>
</tr>
<tr>
<td>P-10-007</td>
<td>Behavioral Activation for Negative Symptoms (BANS-NL): a nurse intervention for psychotic disorders</td>
<td>A. Malda, Leeuwarden, The Netherlands M. Pijnenborg, N. Boonstra, A. Aleman</td>
</tr>
<tr>
<td>P-10-008</td>
<td>Comparing psychological interventions of different complexities with clinical outcomes in a high risk or psychotic adolescent sample</td>
<td>P. Palombi, Roma, Italy A. Marconi, G. Colafrancesco, M. Ferrara</td>
</tr>
<tr>
<td>P-10-010</td>
<td>Competitive work and schizophrenia: design of a project aiming at obtaining and keeping a job through supported employment and multifaceted collaboration</td>
<td>T. Kivekäs, Helsinki, Finland K. Ahola, N. Nevala, K.-P. Martimo</td>
</tr>
</tbody>
</table>
P-11-001
Perception of neutral and negative stimuli in unaffected first-degree relatives of patients with schizophrenia
N. Klaasen, Groningen, The Netherlands
J. van der Velde, P. Gromann, M. Swart, E. Opmeer, D. Wiersma, R. Bruggeman, L. de Haan, L. Krabben-dam, A. Aleman

P-11-002
Emotion recognition as a predictor of transition to a psychotic disorder in ultra-high risk patients
M. Schaefer, Parkville, Australia

P-11-003
Mothers of schizophrenia patients: features of executive functions and face recognition
N. Khamenka, Minsk, Belarus
M. Skuhareuskaya

P-11-004
Social cognition, language and social functioning in children with genetic high risk for developing schizophrenia and bipolar disorder
C. J. Christiani, Copenhagen, Denmark

P-11-005
Neurocognitive profiles in 7-year-old offspring of parents with schizophrenia or with bipolar disorder – part of the Danish High Risk and Resilience Study „VIA 7”
N. Hemager, Copenhagen, Denmark

P-11-006
Psychopathology in offspring of parents with schizophrenia or bipolar disorder – Associations with neurodevelopmental disturbances and childhood stress. Part of the Danish high risk and resilience study – VIA 7
D. Ellersgaard, Copenhagen, Denmark

P-11-007
Maturation of mismatch negativity – implications for ultra high risk schizophrenia research
R. Thienel, Waratah, Australia

P-11-008
Comparison of two video-based assessments for abnormal motor behavior in adolescents at risk for psychosis
S. Schiebler, Bern, Switzerland
A. Tolev, K. Stegmayer, D. Hubl, W. Strik, F. Schultzze-Lutter, B. Schimmelmann, S. Walther

P-11-009
Brain activation during self-reflection in ultra-high risk for psychosis
E. Opmeer, Groningen, The Netherlands
E. Liemburg, J. van der Velde, R. Nieboer, L. Wunderink, A. Aleman

P-11-010
Formal thought disorder in high-risk for psychosis individuals
M. Skuhareuskaya, Minsk, Belarus
Y. Fralova, N. Danilevich, E. Kudina

P-11-011
Neurocognition and cathechol-O-methyltransferase Val/Met polymorphism in high-risk for psychosis individuals
M. Skuhareuskaya, Minsk, Belarus
V. Objedkov, I. Halayenka
Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning
M. Armando, Rome, Italy
S. Vicari, P. Girardi, D. Menghini, M. Digilio, M. Pontillo, R. Saba, L. Mazzone, A. Lin, M. Schafer, P. Amminger

White matter abnormalities in first episode psychosis: a DTI study
T. Melicher, Prague, Czech Republic
P. Mikolas, F. Spaniel, J. Horacek, P. Mohr

Processing speed impairment is related to white matter damage in schizophrenia
J. Pena, Bilbao, Spain
O. Rilo, N. Ibarretxe, O. Rusu, A. Loizaga, R. Avila, C. Schretlen, M. Varvaris, N. Ojeda

White matter pathways of the salience system are altered in schizophrenia
T. Bracht, Bern, Switzerland

Grey matter differences between bipolar patients and controls: a voxel-based morphometry meta-analysis
R. Ganzola, Quebec, Canada
S. Duchesne

Incidental radiological findings on brain magnetic resonance imaging in patients with first-episode psychosis and healthy controls
I. Falkenberg, Marburg, Germany
S. Benetti, W. Pettersson-Yeo, P. Dazzan, A. Simmons, S. Williams, P. McGuire

Structural alterations of the visual system in adolescents with first-admission schizophrenia
R. Henze, Heidelberg, Germany
R. Brunner, P. Parzer, M. Freitag, U. Thiemann, F. Resch, B. Stieltjes

Alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first episode of schizophrenic patients
E. Rizos, Athens, Greece
M. Papathanasiou, P. Michalopoulou, E. Laskos, A. Kastania, A. Douzenis, K. Vasilopoulou, I. Liappas

Proton MRS findings in the corpus callosum genu and auditory information processing in young male patients with schizophrenia
I. Lebedeva, Moscow, Russia
N. Semenova, S. Sidorin, V. Kaleda, A. Barkhatova, T. Akhadow
P-13-001
Spatial cognition in schizophrenia patients measured in virtual reality tests based on animal research
M. Rodriguez, Prague, Czech Republic
I. Fajnerova, K. Vlcek, C. Brom, L. Konradova, K. Dvorska, P. Mikolas, D. Levcik, J. Horacek, A. Stuhlik

P-13-002
Mismatch negativity in birds
U. Schall, Callagahn, Australia
B. Müller, C. Kärgel, O. Güntürkün

P-13-003
Sensorimotor learning in stable schizophrenia patients compared to healthy young and elderly controls in two variations of the rotary pursuit
L. De Picker, Antwerp, Belgium
W. Hulstijn, G. Dumont, B. Sabbe

P-13-004
A study of Neurological Soft Signs (NSS) in schizophrenia
C. S. Gupta, New Delhi, India
T. Gupta, S. Pattanayak, S. Aggarwal

P-13-005
Predictive value of executive functions impairment in early-onset schizophrenia spectrum psychosis: 6 years follow-up study
B. Remberk, Warsaw, Poland
A. K. Bazynska, J. Bragoszewska, F. Rybakowski

P-13-007
Neurocognitive predictors of symptom severity in first-episode schizophrenia
C. Mohn, Drammen, Norway
A.-K. Torgalsbøen

P-13-008
Absorption and dissociative detachment, but not compartmentalisation, are associated with psychosis-like experiences in the general population
C. Humpston, London, United Kingdom
V. Bell, M. Mehta, Q. Deeley

P-13-009
Aberrant salience attribution in schizophrenia patients and healthy participants with delusional experiences
S. Diner, Berlin, Germany
A. Pankow, T. Katthagen, S. Koch, L. Deserno, A. Heinz, F. Schlagenhauf

P-13-010
Willed actions and mechanisms of initiation, production and control of cognitive responses in schizophrenia: a cue-based protocol
R. Rinaldi, Mons, Belarus
L. Lefebvre
### S-34 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Humboldt Hall</td>
<td>Obsessive-compulsive symptoms in schizophrenia</td>
<td>M. Zink, Mannheim, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>N. Fineberg, Hertfordshire, United Kingdom</td>
</tr>
</tbody>
</table>

**S-34-001**

Obsessive compulsive symptoms in the early course of psychotic disorders  
F. Schirmbeck, Mannheim, Germany

**S-34-002**

Neurocognitive differences between schizophrenia patients with and without comorbid obsessive-compulsive symptoms  
N. Fineberg, Hertfordshire, United Kingdom  
D. Patel, K. Mukhopadhaya, K. Laws

**S-34-003**

Antiserotonergic antipsychotics such as clozapine induce or aggravate obsessive compulsive symptoms in schizophrenia  
M. Zink, Mannheim, Germany

**S-34-004**

Effectiveness and outcome predictors of cognitive-behavioral therapy for obsessive-compulsive disorder co-occurring with psychosis  
A. Tundo, Rome, Italy  
L. Salvati, L. Cieri, M. Daniele, D. Di Spigno, R. Necci, A. Parena

### S-35 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| 14.30 – 16.00 h | Kleist Hall | Psychological treatments for people with schizophrenia               | S. Ochoa, Sant Boi de Llobregat, Spain  
J. Usall, Sant Boi de Llobregat, Spain |

**S-35-001**

REPYFLEC cognitive remediation group training in schizophrenia – looking for an integrative approach  
J. Usall, Sant Boi de Llobregat, Spain  
A. Farreny

**S-35-002**

Metacognitive training in schizophrenia (MCT): immediate, delayed and „sleeper“ effects  
S. Moritz, Hamburg, Germany

**S-35-003**

Cognitive-behavioral therapy for people with auditory hallucinations  
E. Lorente, Valencia, Spain

**S-35-004**

A randomized, controlled trial of neurocognitive training in schizophrenia  
M. Linke, Warsaw, Poland  
M. Jarema, A. Wichniak, K. Jankowski
S-36 SYMPOSIA
14.30 – 16.00 h Loft A
Animal models of schizophrenia facing the complexity of genotype, environmental factors and phenotype
Chairs: R. Wolf, Bochum, Germany
M. von Wilmsdorff, Düsseldorf, Germany

S-36-001
Differences in social behavior, prepulse inhibition, dopaminergic and serotonergic hippocampal fiber density of CPB-K mice compared to BALB/cJ mice
P. Panther, Magdeburg, Germany
S. Nullmeier, A. Kröber, S. Herbert, R. Wolf

S-36-002
Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding, deficits in prepulse inhibition and regional c-Fos protein expression
L. Wischhof, Bremen, Germany
M. Koch

S-36-003
Disturbed gene expression caused by perinatal hypoxia in an animal model of schizophrenia
A. Schmitt, Munich, Germany
P. Gebicke-Härter, P. Falkai

S-36-004
Sex-dependent metabolic changes caused by drug treatment with haloperidol and clozapine in rats
M. von Wilmsdorff, Düsseldorf, Germany

O-07 ORAL PRESENTATIONS
14.30 – 16.00 h Einstein Hall
Structural neuroimaging
Chairs: U. Schall, Callaghan, Australia

O-07-001
Factors associating to brain volume change in schizophrenia – the Northern Finland 1966 Birth Cohort
S. Huhtaniska, Oulu, Finland

O-07-002
Familial and unique environmental influences on brain volumes in twins with schizophrenia
M. Picchioni, Northampton, United Kingdom

O-07-003
Greater reductions in grey matter volume in a cognitive-deficit subtype of schizophrenia
A. Shepherd, Darlinghurst, Sydney, Australia
J. Wong, M. Dragovic, K. Laurens, A. Jablensky, V. Carr, M. Green

O-07-004
Supplementary motor area (SMA) volume correlates with psychotic symptoms associated with dysregulation of the motor system – A voxel-based morphometry (VBM) study
K. Stegmayer, Bern, Switzerland
H. Horn, A. Federspiel, N. Razavi, K. Laimböck, T. Bracht, W. Strik, T. Müller, R. Wiest, S. Walther

O-07-005
Relevance of posterior parietal areas for auditory verbal hallucination in schizophrenia: a voxel-based grey and white matter morphometry study
M.-J. van Tol, Groningen, The Netherlands
L. van der Meer, R. Bruggeman, G. Modinos, H. Knegtering, A. Aleman

O-07-006
Structural brain imaging correlates of At-Risk Mental State
U. Schall, Callaghan, Australia
T. Ehlkes, P. Michie, R. Atkinson, P. Ward
URANIA, THIRD LEVEL
Lofts A, B and C with access via elevator on floor.

ACKNOWLEDGMENTS

The organisers of the 4th European Conference on Schizophrenia Research (ECSR) gratefully acknowledge the support of:

Roche Pharma AG in terms of sponsoring (EUR 10.000)

German Research Association (DFG) in terms of an educational grant
Anzeige